» Articles » PMID: 19076443

Multinuclear Magnetic Resonance Spectroscopy for in Vivo Assessment of Mitochondrial Dysfunction in Parkinson's Disease

Overview
Specialty Science
Date 2008 Dec 17
PMID 19076443
Citations 33
Authors
Affiliations
Soon will be listed here.
Abstract

Parkinson's disease (PD) is a common and often devastating neurodegenerative disease affecting up to one million individuals in the United States alone. Multiple lines of evidence support mitochondrial dysfunction as a primary or secondary event in PD pathogenesis; a better understanding, therefore, of how mitochondrial function is altered in vivo in brain tissue in PD is a critical step toward developing potential PD biomarkers. In vivo study of mitochondrial metabolism in human subjects has previously been technically challenging. However, proton and phosphorus magnetic resonance spectroscopy ((1)H and (31)P MRS) are powerful noninvasive techniques that allow evaluation in vivo of lactate, a marker of anaerobic glycolysis, and high energy phosphates, such as adenosine triphosphate and phosphocreatine, directly reflecting mitochondrial function. This article reviews previous (1)H and (31)P MRS studies in PD, which demonstrate metabolic abnormalities consistent with mitochondrial dysfunction, and then presents recent (1)H MRS data revealing abnormally elevated lactate levels in PD subjects.

Citing Articles

Refining the clinical diagnosis of Parkinson's disease.

Mulroy E, Erro R, Bhatia K, Hallett M Parkinsonism Relat Disord. 2024; 122:106041.

PMID: 38360507 PMC: 11069446. DOI: 10.1016/j.parkreldis.2024.106041.


Transcriptome-based biomarker prediction for Parkinson's disease using genome-scale metabolic modeling.

Abdik E, Cakir T Sci Rep. 2024; 14(1):585.

PMID: 38182712 PMC: 10770157. DOI: 10.1038/s41598-023-51034-y.


Brain proton magnetic resonance spectroscopy in patients with Parkinson's disease.

Shoeibi A, Verdipour M, Hoseini A, Moshfegh M, Olfati N, Layegh P Curr J Neurol. 2023; 21(3):156-161.

PMID: 38011354 PMC: 10082953. DOI: 10.18502/cjn.v21i3.11108.


A Double-Blind, Randomized, Placebo-Controlled Trial of Ursodeoxycholic Acid (UDCA) in Parkinson's Disease.

Payne T, Appleby M, Buckley E, van Gelder L, Mullish B, Sassani M Mov Disord. 2023; 38(8):1493-1502.

PMID: 37246815 PMC: 10527073. DOI: 10.1002/mds.29450.


Effects of sex and APOE ε4 genotype on brain mitochondrial high-energy phosphates in midlife individuals at risk for Alzheimer's disease: A 31Phosphorus MR spectroscopy study.

Jett S, Dyke J, Yepez C, Zarate C, Carlton C, Schelbaum E PLoS One. 2023; 18(2):e0281302.

PMID: 36787293 PMC: 9928085. DOI: 10.1371/journal.pone.0281302.